Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person BGJ398 [cytosol]

Class:Id	ChemicalDrug:2038925
_displayName	BGJ398 [cytosol]
_timestamp	2018-12-12 00:29:46
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:2038924] Rothfels, K, 2012-01-10
crossReference	[DatabaseIdentifier:9628071] ChEBI:63451
disease	[Disease:1500689] cancer
modified	[InstanceEdit:2067725] Rothfels, K, 2012-01-25 [InstanceEdit:9603959] Rothfels, Karen, 2018-03-28 [InstanceEdit:9608018] Weiser, JD [InstanceEdit:9616752] Shorser, Solomon, 2018-08-13 [InstanceEdit:9619952] Wu, G, 2018-09-19 [InstanceEdit:9627975] Wu, G, 2018-11-05 [InstanceEdit:9631716] Wu, G, 2018-12-12
name	BGJ398 BGJ-398
referenceEntity	[ReferenceTherapeutic:9603952] BGJ-398 [Guide to Pharmacology:7877]
stableIdentifier	[StableIdentifier:2296164] R-ALL-2038925.2
summation	[Summation:2067706] A pan-FGFR ATP-competitive inhibitor that is in phase I clin...
(hasMember)	[DefinedSet:2023441] Tyrosine kinase inhibitors of overexpressed FGFR1 [cytosol] [DefinedSet:2029965] Tyrosine kinase inhibitors of overexpressed FGFR2 [cytosol] [DefinedSet:2077403] Tyrosine kinase inhibitors of FGFR2 mutants [cytosol] [DefinedSet:2077416] Tyrosine kinase inhibitors of FGFR3 mutants [cytosol]
[Change default viewing format]

No pathways have been reviewed or authored by BGJ398 [cytosol] (2038925)